Is bosutinib/bosutinib available in China?

Bosutinib/Bosutinib was approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (< /span>EMA) for the treatment of adult patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) who are resistant to or intolerant to prior therapy, which may includechronic, accelerated, or blast phasePh+ CML, sold under the trade name BOSULIF.

In September 2023, bosutinib was also approved by the FDA for the treatment of CML in children who are newly diagnosed or who are resistant/intolerant to previous treatments. According to its clinical trial results, bosutinib has been proven to be effective in improving the condition of patients with chronic myelogenous leukemia, especially in cases of resistance or intolerance to previous treatments. Its improvement in major molecular responses is particularly significant.

However, as of the end of January 2025, bosutinib has not yet been officially launched in China, which means that Chinese patients currently have no way to obtain the drug through formal channels. At the same time, due to bosutinib's wide application in the international market and its good efficacy, many patients and medical institutions are looking forward to its launch in China. In clinical practice, the use of bosutinib is also affected by various factors such as medical policies, market access, and medical insurance reimbursement.

The side effects of bosutinib are generally considered controllable and mainly include gastrointestinal reactions, liver function damage, hematological abnormalities, etc. However, the incidence and severity of these side effects vary among individual patients, so the patient's physical condition needs to be closely monitored during treatment. Bosutinib undoubtedly provides a new treatment option for patients who have developed resistance to other therapies.

Reference materials:https://en.wikipedia.org/wiki/Bosutinib